See the DrugPatentWatch profile for Spravato
Spravato generated $202.3 million in US sales during the first quarter of 2023 [1].
How did Spravato perform in US sales for the full year 2023?
For the full year 2023, Spravato reported US sales of $773 million [2]. This marked a 14% increase compared to the previous year [2].
What is Spravato and what is it used for?
Spravato is a brand name for esketamine nasal spray [3]. It is indicated for the treatment of treatment-resistant depression in adults and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior [3].
When does Spravato's patent expire?
Information regarding the specific patent expiry dates for Spravato is available through resources like DrugPatentWatch.com [4]. Patents for pharmaceuticals are complex and can involve multiple patents covering different aspects of the drug, such as formulation, method of use, and manufacturing [4].
Who are Spravato's competitors?
Spravato operates in the mental health treatment landscape, facing competition from various antidepressants and other therapies for treatment-resistant depression. This includes established antidepressants and emerging treatments for major depressive disorder [5].
What are the risks associated with Spravato?
Spravato carries a Risk Evaluation and Mitigation Strategy (REMS) due to potential risks, including sedation, dissociation, and abuse or misuse [3]. Patients must be monitored for at least two hours after administration, and the REMS program ensures safe prescribing and dispensing [3].